27th June 2022 | Pharma Updates
Indian Pharmaceutical Alliance urges against price controls on inexpensive drugs
As per the president and CEO of Torrent Pharma and the IPA, manufacturers of scheduled medications are losing money due to the rising volatility of raw material prices and their inability to raise prices.
NTAGI examine trial results for SII's qHPV cervical cancer vaccine
The trial data for India’s first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer would likely be reviewed by the National Technical Advisory Group on Immunization (NTAGI) on June 28.
GSK moves closer to a functional cure with promising hep B data
Millions of people with a persistent infection may soon have hope thanks to an interim review of GSK’s investigational hepatitis B medication bepirovirsen in a mid-stage research.
Pharma firms urged by the health minister to adhere to safety procedures
As per the health minister, the management of the pharmaceutical industries should adhere to all safety precautions that should be implemented to prevent accidents and pollution.
Biocon hires an outside law firm to investigate consultant governance
According to top executive at Bengaluru-based biopharmaceutical company, Biocon has hired an outside law firm to conduct a thorough assessment of its present governance practises involving its consultants and contractors.
Roche wary to investing further in cancer treatments using "guided-missile" ADC technology
Despite receiving increased attention in the pharmaceutical sector, Roche is still hesitant to invest more in antibody-drug conjugates, which have been named “guided-missile” cancer treatments.
Dr. Reddy's acquires branded and generic injectables from Eton Pharma in US
According to a regulatory filing with the bourses, Dr Reddy’s paid an upfront cash payment of roughly $5 million to buy the Eton portfolio, plus contingent payments that might total up to $45 million.